Search

Displaying results 5451 - 5460 of 6949 in total
  1. Drug

    Fenpiprane

    go.drugbank.com/drugs/DB13439
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  2. Drug

    Lucatumumab

    go.drugbank.com/drugs/DB06360
    Investigational

  3. Drug

    Decyl(dimethyl)phosphine oxide

    go.drugbank.com/drugs/DB07641
    Experimental

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  4. Target

    COUP transcription factor 1

    go.drugbank.com/bio_entities/BE0008953
    TargetHumans

    Coup (chicken ovalbumin upstream promoter) transcription factor binds to the ovalbumin promoter and, in conjunction with another protein (S300-II) stimulates initiation of transcription. Binds to both direct repeats and palindromes of th...

    Synonyms: Nuclear receptor subfamily 2 group F member 1
  5. Drug

    Becatecarin

    go.drugbank.com/drugs/DB06362
    Investigational

    Becatecarin is a derivative of rebeccamycin.

  6. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to ...

  7. Drug

    HGTV-43

    go.drugbank.com/drugs/DB05807
    Experimental

    HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.

  8. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus. It is developed by C...

  9. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). … The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp.

  10. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].